Data / Form D filings / Biolexis Therapeutics Inc.
Biolexis Therapeutics Inc.: Form D filings
Biolexis Therapeutics Inc., a biotechnology company in Lehi, UT, filed 5 Form D notices with the SEC between 2022 and 2026. The latest, on June 3, 2026, reports $1.6 million sold of a $12 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3900 N TRAVERSE MOUNTAIN BLVD SUITE 200, Lehi, UT, 84043
- Phone
- (801) 328-3600
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1914060
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | New notice | $12,000,000 | $1,600,000 | $10,400,000 | 2 | May 20, 2026 | sec.gov |
| Oct 17, 2023 | New notice | Indefinite | $1,000,000 | 1 | Oct 3, 2023 | sec.gov | |
| Oct 3, 2023 | New notice | $725,000 | $725,000 | 6 | Sep 19, 2023 | sec.gov | |
| Sep 2, 2022 | New notice | Indefinite | $1,500,000 | 2 | Aug 18, 2022 | sec.gov | |
| Mar 1, 2022 | New notice | $2,000,000 | $1,500,000 | $500,000 | 17 | Feb 3, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Tyler Hartmann | Executive Officer | |
| David J. Bearss | Director | |
| Hariprasad Vankayalapati | Director | |
| James N. Clarke | Director | |
| Anthony Steve | Director |
Other biotechnology companies in Utah that filed recently
- Life Impact Partners 1 LLC offering · Oct 22, 2026
- 3Helix, Inc. $7.8 million · Sep 21, 2026
- Halia Therapeutics, Inc. $3.5 million · Aug 31, 2026
- Paterna BioSciences HoldCo Inc. $6.3 million · Aug 12, 2026
Every Form D from the week of Jun 1, 2026 · All recent filings in Utah · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Biolexis Therapeutics Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.